CAINA TECHNOLOGY CO.(301122)

Search documents
采纳股份(301122) - 2024年度独立董事述职报告(刘斌)
2025-04-24 14:32
采纳科技股份有限公司 2024 年度独立董事述职报告 (独立董事:刘斌) 本人作为采纳科技股份有限公司(以下简称"公司")的独立董事, 严格 按照《中华人民共和国公司法》(以下简称"《公司法》")《上市公司独立董事 管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规范性文件 以及《采纳科技股份有限公司章程》(以下简称"《公司章程》")《采纳科技股 份有限公司独立董事工作制度》(以下简称"《独立董事工作制度》")的规定 和要求,勤勉尽责履行独立董事的职责,始终站在独立公正的立场参与公司决策, 充分发挥独立董事的作用,积极促进公司健全内控制度及规范运作,维护公司全 体股东尤其是中小股东的合法利益。现将 2024 年度履行独立董事职责的工作情 况报告如下: 一、独立董事的基本情况 刘斌,男,1972 年生,中国国籍,无永久境外居留权,大专学历,注册会 计师、注册税务师、注册资产评估师、注册房地产估价师;中国人民政治协商会 议江阴市第十五届委员会委员、第十六届委员会委员、常委;江阴市第十八届人 大常委会计划和预算审查咨询专家。现 ...
采纳股份:2024年报净利润0.53亿 同比下降53.1%
Tong Hua Shun Cai Bao· 2025-04-24 14:27
前十大流通股东累计持有: 1297.46万股,累计占流通股比: 29.32% 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益(元) | 0.4300 | 0.9200 | -53.26 | 1.7600 | | 每股净资产(元) | 14.81 | 14.78 | 0.2 | 18.46 | | 每股公积金(元) | 9.63 | 9.63 | 0 | 12.82 | | 每股未分配利润(元) | 3.91 | 3.90 | 0.26 | 4.37 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.88 | 4.1 | -5.37 | 4.65 | | 净利润(亿元) | 0.53 | 1.13 | -53.1 | 1.62 | | 净资产收益率(%) | 2.94 | 6.37 | -53.85 | 10.28 | 数据四舍五入,查看更多财务数据>> 二、前10名无限售条件股东持股情况 10派2. ...
采纳股份(301122) - 2024 Q4 - 年度财报
2025-04-24 13:55
Financial Performance - The net profit attributable to shareholders decreased by 52.83% compared to the previous year, primarily due to the impact of FDA import warnings affecting product sales and the provision for impairment of inventory and receivables [4]. - The company's operating revenue for 2024 was ¥387,893,051.46, a decrease of 5.50% compared to ¥410,470,639.42 in 2023 [18]. - Net profit attributable to shareholders for 2024 was ¥53,093,764.34, down 52.83% from ¥112,564,144.08 in 2023 [18]. - The basic earnings per share for 2024 was ¥0.43, reflecting a decline of 53.26% from ¥0.92 in 2023 [18]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, which was ¥32,075,608.69 in 2024, down 62.20% from ¥84,858,023.76 in 2023 [18]. - Revenue from the medical device segment was 198.72 million yuan, a decline of 23.56%, accounting for 51.23% of total revenue [61]. - The animal device segment saw revenue increase to 151.39 million yuan, up 20.83%, representing 39.03% of total revenue [61]. - Laboratory consumables revenue surged to 29.54 million yuan, a growth of 66.08%, making up 7.61% of total revenue [61]. Risk Management - There are no significant risks to the company's ongoing operations, and the medical device industry does not face issues such as overcapacity or continuous decline [4]. - The company has outlined potential risk factors and countermeasures in the management discussion and analysis section of the report [4]. - Future development outlooks and forward-looking statements do not constitute substantive commitments to investors, emphasizing the need for rational investment and risk awareness [4]. - The company emphasizes the importance of investor attention to the outlined risk factors and strategies for future development [4]. - The company faces risks related to customer concentration, with the top five clients accounting for a significant portion of revenue, necessitating diversification strategies [118]. - The company is also aware of foreign exchange risks due to its export-oriented sales, primarily denominated in USD, and plans to implement measures to mitigate these risks [120]. Research and Development - The company continues to focus on research and development of new products and technologies, although specific details were not disclosed in the report [4]. - The company has a dedicated R&D team focused on innovation, with established research centers for veterinary puncture instruments and safety syringes [51][52]. - R&D expenses rose by 23.13% year-on-year to CNY 26,394,205.40, reflecting ongoing investment in product development [72]. - R&D investment reached ¥26,394,205.40 in 2024, up from ¥21,436,278.35 in 2023, marking a year-over-year increase of 23.5% [75]. - The company has developed a range of safety products, including "safety insulin syringes" and "safety blood collection needles," aligning with market trends towards safer medical devices [55]. - The company is developing an automated sheath injector to reduce labor costs and improve production efficiency [71]. - The company has completed the development of a precision urine collector, which enhances measurement accuracy for clinical diagnostics [73]. - The company is working on a safety self-destroying indwelling needle to minimize the risk of blood exposure and infection [73]. Market Expansion and Strategy - The company is actively exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position [4]. - The company is actively expanding its overseas factory construction and entering emerging markets to mitigate the impact of U.S. tariffs [59]. - The company plans to enhance product R&D efforts to develop high-value products and improve risk resilience [59]. - The company aims to strengthen its market position in high-safety and high-value products while actively expanding its market share [35]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan for potential deals [157]. Corporate Governance - The company has established a comprehensive governance structure, ensuring compliance with relevant laws and regulations, and maintaining effective communication with shareholders through various channels [128]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure and adherence to regulatory requirements [130]. - The company has a structured governance framework including a shareholders' meeting, board of directors, and supervisory board, ensuring operational independence [139]. - The company has established a remuneration and assessment committee in compliance with relevant laws and regulations [160]. - The company has implemented a "Quality Return Dual Improvement" action plan to enhance product quality and customer satisfaction, although specific details on its disclosure were not provided [126]. Employee and Talent Management - The company has a competitive salary policy, combining base salary and performance-based pay, ensuring compliance with national labor laws [177]. - The company emphasizes talent development through targeted training programs and internal cultural enrichment to enhance employee skills and engagement [178]. - The total number of employees at the end of the reporting period is 783, with 499 in production, 138 in technical roles, and 110 in administration [176]. - The total number of employees with a bachelor's degree or above is 105, indicating a focus on educational qualifications within the workforce [176]. - The company has established a long-term incentive mechanism for core employees through indirect shareholding arrangements [185]. Financial Management - The company reported a total investment of 109,726.24 million RMB for the year 2022, with 20,000 million RMB allocated for liquidity support [104]. - The company has committed to using the raised funds for promised investment projects without any significant violations [101]. - The company has not reported any issues or other circumstances regarding the use and disclosure of raised funds [105]. - The company has a clear exit mechanism for employees who leave under specific circumstances, ensuring the protection of company interests [190]. - The internal control audit report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024, in all material respects [198].
采纳股份(301122) - 2025 Q1 - 季度财报
2025-04-24 13:55
Financial Performance - The company's operating revenue for Q1 2025 was ¥72,709,290.01, a decrease of 34.28% compared to ¥110,633,038.63 in the same period last year[5] - Net profit attributable to shareholders was ¥7,680,170.44, down 69.34% from ¥25,045,442.29 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥3,751,442.88, reflecting a decline of 78.81% compared to ¥17,703,983.31 in the previous year[5] - Basic and diluted earnings per share were both ¥0.06, a decrease of 70.00% from ¥0.20 in the same period last year[5] - Operating profit for the current period was ¥8,771,668.48, down 70.4% from ¥29,566,811.75 in the previous period[26] - Net profit for the current period was ¥7,263,799.94, a decline of 70.0% compared to ¥25,045,442.29 in the previous period[26] - Total comprehensive income attributable to the parent company was 7,676,341.95, compared to 25,045,442.29 in the previous period[27] Cash Flow and Assets - The net cash flow from operating activities decreased by 40.24%, amounting to ¥24,974,256.66, down from ¥41,790,114.16 in the previous year[11] - The company's cash and cash equivalents decreased to ¥323,052,115.34 from ¥331,714,012.93, a reduction of 2.0%[21] - Total current assets decreased to ¥1,025,083,767.94 from ¥1,134,334,117.19, a decline of 9.6%[21] - Total non-current assets increased to ¥944,403,424.89 from ¥846,590,930.24, an increase of 11.5%[22] - Total liabilities decreased to ¥147,823,364.57 from ¥166,483,138.90, a reduction of 11.1%[23] - Total equity increased to ¥1,821,663,828.26 from ¥1,814,441,908.53, an increase of 0.1%[23] - Cash inflow from investment activities totaled 608,289,255.61, compared to 317,427,371.11 in the previous period, indicating a significant increase[30] - Cash flow from operating activities decreased by 15% year-over-year[29] - The company’s total cash outflow from operating activities was 83,163,457.06, slightly down from 85,841,219.67 in the previous period[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,731[14] - The largest shareholder, Lu Jun, holds 28.29% of shares, totaling 34,580,000 shares, with 25,935,000 shares pledged[14] - The second-largest shareholder, Lu Weiwei, holds 16.16% of shares, totaling 19,760,000 shares[14] - The top ten shareholders collectively hold significant stakes, with the top three shareholders alone accounting for over 50% of total shares[14] - The company has not disclosed any other significant shareholder relationships or actions that may affect shareholding dynamics[15] - The company is under high executive lock-up restrictions, with all major shareholders' shares subject to lock-up during their tenure[17] Operational Challenges - The company is currently facing an FDA import warning affecting its subsidiary, Jiangsu Caina Medical Technology Co., which may significantly impact future revenue and profits[19] - The company is actively communicating with the FDA to resolve the import warning issue, but the timeline for resolution remains uncertain[19] - The company emphasizes the importance of investor awareness regarding potential risks associated with the FDA warning[19] Other Financial Metrics - Total operating costs decreased to ¥69,274,853.76 from ¥79,627,515.63, reflecting a reduction of 13.0%[25] - Investment income decreased by 59.70% to ¥2,128,789.69, down from ¥5,281,918.63 in the previous year due to reduced interest from redeemed financial products[10] - The company experienced a 97.54% reduction in asset impairment losses, reporting a loss of ¥291,950.27 compared to a loss of ¥11,871,141.16 in the previous year, primarily due to prior year provisions related to FDA issues[10] - The company incurred a foreign currency translation loss of -3,828.49[27]
采纳股份(301122) - 关于2025年度公司董事、监事及高级管理人员薪酬方案的公告
2025-04-24 13:54
证券代码:301122 证券简称:采纳股份 公告编号:2025-029 采纳科技股份有限公司 关于 2025 年度公司董事、监事及高级管理人员 薪酬方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司(以下简称"公司")于 2025 年 4 月 23 日召开了第 三届董事会第十三次会议、第三届监事会第十二次会议,分别审议通过了《关于 2025 年度公司董事薪酬方案的议案》《关于 2025 年度公司高级管理人员薪酬方 案的议案》《关于 2025 年度公司监事薪酬方案的议案》,其中董事、监事的薪 酬方案尚需提交公司年度股东大会审议。具体薪酬方案如下: 独立董事薪酬为 7 万/年(含税)。 2、监事薪酬方案 在公司担任其他职务的监事,按照其在公司担任的其他职务,依据公司相关 薪酬标准与绩效考核领取薪酬,不单独发放监事津贴,未在公司担任其他职务的 监事,不在公司领取薪酬、监事津贴。 3、高级管理人员薪酬方案 高级管理人员按照其在公司担任的具体事务、实际工作绩效并结合公司经 营业绩等综合评定薪酬。 1 / 2 一、薪酬方案情况 结合公司实际经 ...
采纳股份(301122) - 2024年度募集资金存放与使用情况的专项报告
2025-04-24 13:54
根据中国证监会《上市公司监管指引第 2 号—上市公司募集资金管理和使用 的监管要求》、深圳证券交易所《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》有关规定,采纳科技股份有限公司 (以下简称 "公司")编制了 2024 年度(以下简称"报告期"或"本报告期")募集资金存 放与使用情况的专项报告,具体说明如下: 一、募集资金基本情况 (一)实际募集资金金额、资金到账时间 本公司经中国证券监督管理委员会证监发行字[2021]3937号文核准,由主承 销商通过交易所系统采用网下向配售对象配售和网上资金申购定价发行相结合 的方式,向社会公开发行了人民币普通股(A股)股票2,350.88万股,发行价为每 股人民币为50.31元,共计募集资金总额为人民币118,272.77万元,扣除券商承 销佣金及保荐费7,252.57万元后,主承销商于2022年1月21日汇入本公司募集资 金监管账户人民币111,020.20万元。另扣减招股说明书印刷费、审计费、律师费、 评估费和网上发行手续费等与发行权益性证券相关的新增外部费用1,293.96万 元后,公司本次募集资金净额为109,726.24万元。上述募 ...
采纳股份(301122) - 独立董事独立性自查情况(王尚虎)
2025-04-24 13:54
独立董事独立性自查情况 8、本人符合《上市公司独立董事管理办法》第六条规定的独立性要求。 本人保证上述自查内容真实、准确、完整,没有虚假记载、误导性陈述或重 大遗漏;否则,本人愿意承担由此引起的法律责任和接受深圳证券交易所的自律 监管措施或纪律处分。 3、本人及本人直系亲属不在直接或间接持有贵司已发行股份 5%以上的股 东单位任职,也不在贵司前五名股东单位任职; 4、本人及本人直系亲属不在贵司控股股东、实际控制人及其附属企业任职; 5、本人不是为贵司及其控股股东、实际控制人或者其各自附属企业提供财 务、法律、咨询等服务的人员; 6、本人未与贵司及其控股股东、实际控制人或者其各自的附属企业有重大 业务往来的单位任职,也不在有重大业务往来单位的控股股东单位任职; 7、本人在最近十二个月内不具有前六项所列任一种情形; 采纳科技股份有限公司董事会: 本人王尚虎根据《上市公司独立董事管理办法》等相关法规、规范性文件要 求,就本人符合独立董事独立性任职资格情况进行自查,自查情况如下: 1、本人除担任贵司独立董事外,本人及本人直系亲属、主要社会关系均不 在贵司及其附属企业任职; 2、本人及本人直系亲属不是直接或间接持有贵司 ...
采纳股份(301122) - 关于聘请2025年度财务及内部控制审计机构的公告
2025-04-24 13:54
证券代码:301122 证券简称:采纳股份 公告编号:2025-028 采纳科技股份有限公司 关于聘请 2025 年度财务及内部控制审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司(以下简称"公司")于 2025 年 4 月 23 日召开了第 三届董事会第十三次会议、第三届监事会第十二次会议,分别审议通过《关于聘 请 2025 年度财务及内部控制审计机构的议案》,拟聘请中汇会计师事务所(特殊 普通合伙)(以下简称"中汇会计师事务所")为公司 2025 年度财务及内部控制 审计机构,该事项尚需提交公司 2024 年年度股东大会审议。现将相关情况公告 如下: 一、拟聘任的会计师事务所基本情况 (一)机构信息 1、基本信息 机构名称:中汇会计师事务所(特殊普通合伙) 机构性质:特殊普通合伙企业 统一社会信用代码:91330000087374063A 业务资质:会计师事务所执业证书 是否曾从事过证券服务业务:是 2、人员信息 首席合伙人:高峰 上年度末(2024 年 12 月 31 日)合伙人数量:116 人,上年度末注册会计 师人 ...
采纳股份(301122) - 独立董事独立性自查情况(夏立扬)
2025-04-24 13:54
3、本人及本人直系亲属不在直接或间接持有贵司已发行股份 5%以上的股 东单位任职,也不在贵司前五名股东单位任职; 4、本人及本人直系亲属不在贵司控股股东、实际控制人及其附属企业任职; 5、本人不是为贵司及其控股股东、实际控制人或者其各自附属企业提供财 务、法律、咨询等服务的人员; 独立董事独立性自查情况 采纳科技股份有限公司董事会: 本人夏立扬根据《上市公司独立董事管理办法》等相关法规、规范性文件要 求,就本人符合独立董事独立性任职资格情况进行自查,自查情况如下: 1、本人除担任贵司独立董事外,本人及本人直系亲属、主要社会关系均不 在贵司及其附属企业任职; 2、本人及本人直系亲属不是直接或间接持有贵司已发行股份 1%以上的股 东,也不是贵司前十名股东中自然人股东; 2025 年 4 月 23 日 1 / 1 6、本人未与贵司及其控股股东、实际控制人或者其各自的附属企业有重大 业务往来的单位任职,也不在有重大业务往来单位的控股股东单位任职; 7、本人在最近十二个月内不具有前六项所列任一种情形; 8、本人符合《上市公司独立董事管理办法》第六条规定的独立性要求。 本人保证上述自查内容真实、准确、完整,没有虚假记载、 ...
采纳股份(301122) - 关于2024年度计提减值准备的公告
2025-04-24 13:54
证券代码:301122 证券简称:采纳股份 公告编号:2025-030 采纳科技股份有限公司 关于 2024 年度计提减值准备的公告 采纳科技股份有限公司(以下简称"公司")根据《企业会计准则》及《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 相关规定,对公司及下属子公司各类资产进行了全面核查和减值测试,拟对截至 2024 年 12 月 31 日存在减值迹象的相关资产计提相应减值准备。现将本报告期 (或"本期",指 2024 年全年,下同)内计提资产减值准备的具体情况公告如 下: 一、本次计提减值准备的情况 经过公司及下属子公司对截至 2024 年 12 月 31 日存在可能发生减值迹象的 资产进行全面清查和减值测试后,计提各项减值准备明细情况如下: | 类别 | 项目 | 本期计提 | 情况说明 | | --- | --- | --- | --- | | | | (万元) | | | 信用减值损失 | 应收款项坏账 | 1,693.80 | 根据公司会计政策对应收款项以预期 信用损失为基础确认的当期损失。并 | | | 损失 | | 根据美国 FDA 事件影响,公司按预计 | ...